Spruce Biosciences, Inc. (SPRBD)
OTCMKTS · Delayed Price · Currency is USD
7.00
-0.50 (-6.67%)
At close: Aug 29, 2025
Spruce Biosciences Employees
Spruce Biosciences had 21 employees as of December 31, 2024. The number of employees decreased by 8 or -27.59% compared to the previous year.
Employees
21
Change (1Y)
-8
Growth (1Y)
-27.59%
Revenue / Employee
$144,333
Profits / Employee
-$5,370,889
Market Cap
3.94M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21 | -8 | -27.59% |
Dec 31, 2023 | 29 | 2 | 7.41% |
Dec 31, 2022 | 27 | 12 | 80.00% |
Dec 31, 2021 | 15 | -2 | -11.76% |
Dec 31, 2020 | 17 | 2 | 13.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Elite Pharmaceuticals | 68 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Longduoduo Company | 49 |
Spruce Biosciences News
- 16 days ago - Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 16 days ago - Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 5 weeks ago - Spruce Biosciences Announces Reverse Stock Split - Business Wire
- 5 weeks ago - HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - GlobeNewsWire
- 2 months ago - Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market - Business Wire
- 4 months ago - Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 4 months ago - Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript) - Seeking Alpha
- 4 months ago - Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire